Chemistry and biological activity of new 3-benzazepines

International Journal of Antimicrobial Agents

Volumn 14, Issue 3, 2000, Pages 193-201

  Kawase, Masami ^a   Saito, Setsuo ^a   Motohashi, Noboru ^b  

^a JOSAI UNIVERSITY   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

3 Benzazepine derivatives; Antiretroviral effect; Cytotoxicity; Multidrug resistance; Plasmid; Radical generation

Indexed keywords

3 BENZAZEPINE DERIVATIVE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ASCORBIC ACID; EMONAPRIDE; RADICAL; VERAPAMIL;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BRAIN HOMOGENATE; CELL STRAIN HL 60; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; LEUKEMIA VIRUS; LYMPHOMA CELL; MULTIDRUG RESISTANCE; NONHUMAN; PLASMID; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034074351     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00155-7     Document Type: Article

References (45)

1. Weinstock J., Hieble J.P., Wilson J.W. The chemistry and pharmacology of 3-benzazepines. Drugs Future. 10:1985;645-696.
2. Giering J.E., Davidson T.A., Shetty B.V., Truant A.P. Narcotic antagonist activity of substituted 1,2,4,5-tetrahydro-3H,3-benzazepines. Narcotic antagonists. Braude M.C., Harris L.S., May E.L., Smith J.P., Villarreal J.E. Advances in Biochemical Psychopharmacology. 8:1974;167-186 Raven Press, New York.
3. Kawase M., Motohashi N., Chakrabarty A.N. et al. Cytotoxic activity and radical intensity of 3-benzazopine derivatives. Chakrabarty A.N., Molnár J., Dastidar S.G., Motohashi N. Non Antibiotics. 1998;NISCOM, New Delhi, India.
4. Molnár J., Szabo D., Miskolci C. et al. The effect of some new 3-benzazepines on plasmid DNA, mdr P-glycoprotein and reverse transcriptase leukaemia. Chakrabarty A.N., Molnár J., Dastidar S.G., Motohashi N. Non Antibiotics. 1998;NISCOM, New Delhi, India.
5. Kawase M., Motohashi N., Kurihara T. et al. Relationship between radical intensity and cytotoxic activity of dopamine-related compounds. Anticancer Res. 18:1998;1069-1074.
6. Kametani T., Fukumoto K. Synthesis of benzazepine alkaloids and related compounds. Heterocycles. 3:1975;931-1004.
7. Kawase M., Motohashi N., Niwa M., Nozaki M. Use of the triflamide group for Friedel-Crafts acylation of N-(β-phenethyl)amino acids to 3-benzazepine derivatives. Heterocycles. 45:1997;1121-1129.
8. Kawase M., Niwa M., Nozaki M., Motohashi N. Synthesis of 2-trifluoromethyl-2,3,4,5-tetrahydro-1H-3-benzazepine derivatives. Heterocycles. 48:1998;555-560.
9. Proctor GR, Thomson RH. Azabenzocycloheptenones. Part 1. The Friedel Crafts reaction with aryl-amino-acids, J Chem Soc 1957;2302-2311.
10. Kawase M., Okada Y., Miyamae H. The Dakin West reaction of N-acyl-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acids using trifluoroacetic anhydride: structural revision for the unexpected product. Heterocycles. 48:1998;285-294.
11. Davis F.D., Zhou P., Reddy G.V. Asymmetric synthesis and reactivities of cis-N-(ρ-toluenesulfinyl)aziridine-2-carboxylic acids. J. Org. Chem. 59:1994;3243-3245.
12. Hickman J.A. Apoptosis induced by anticancer drugs. Cancer Metastasis. 11:1992;121-139.
13. Sakagami H., Satoh K., Fukuchi K., Gomi K., Takeda M. Effect of an iron-chelator on ascorbate induced cytotoxicity. Free Radic. Biol. Med. 23:1997;260-270.
14. Satoh K., Sakagami H., Motohashi N. Radical modulation activity of benzo[a]phenothiazine. Anticancer Res. 17:1997;2539-2544.
15. Iriyama K., Yoshiura M., Iwamoto T., Ozaki Y. Simultaneous determination of uric and ascorbic acids in human serum by reversed-phase high performance liquid chromatography with electrochemical detection. Anal. Biochem. 141:1984;238-243.
16. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., Stitz T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 256:1992;1783-1790.
17. Raderer M., Scheithauer W. Clinical trials of agents that reverse multidrug resistance. Cancer. 72:1993;3553-3563.
18. Aszalos A., Pine P.S., Pandey R., Gottesman M.M. Behavior of N-acylated daunorubicins in mdr1 gene transfected and parental cells. Biochem. Pharm. 50:1995;889-892.
19. Endicott J.A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58:1989;137-171.
20. Li X.-Z., Ma D., Livermore D.M., Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to β-lactam resistance. Antimicrob. Agents Chemother. 38:1994;1742-1752.
21. Clark F.S., Parkinson T., Hitchcock C.A., Gow N.A.R. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob. Agents Chemother. 40:1996;419-425.
22. Gollapudi S., Reddy M., Gangadharam P., Tsuruo T., Gupta S. Mycobacterium tuberculosis induces expression of P-gycoprotein in promonocytic U1 cells chronically infected with HIV type 1. Biochem. Biophys. Res. Commun. 199:1994;1181-1187.
23. Ford J.M., Hait W. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:1990;155-199.
24. Zamora J.M., Pearce H.L., Beck W.T. Physical chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33:1988;454-462.
25. Tsuruo T., lida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1981;1967-1972.
26. Chiba P., Ecker D., Schmid J. et al. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol. Pharmacol. 49:1996;1122-1130.
27. Kiue A., Sano T., Suzuki K. et al. Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents. Cancer Res. 50:1990;310-317.
28. Pajeva I., Wiese M. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. J. Med. Chem. 41:1998;1815-1826.
29. Twentyman P.R. Cyclosporins as drug resistance modifiers. Biochem. Pharmacol. 43:1992;109-117.
30. Dhainaut A., Regnier G., Tizot A. et al. New purines and purine analogs as modulators of multidrug resistance. J. Med. Chem. 39:1996;4099-4108.
31. Hyafil F., Vergely C., Vignaud P.D., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:1993;4595-4602.
32. Sato W., Fukazawa N., Nakanishi O. et al. Reversal of mutidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother. Pharmacol. 35:1995;271-277.
33. Andrus M.B., Lepore S.D., Turner T.M. Total synthesis of stipiamide and designed polyenes as new agents for the reversal of mutidrug resistance. J. Am. Chem. Soc. 119:1997;12159-12169.
34. Kessel D. Exploring multidrug resistance using rhodamine 123. Cancer Commun. 1:1989;145-149.
35. Pileblad E., Slivka A., Bratvold D., Cohen G. Studies on the autoxidation of dopamine: interaction with ascorbate. Arch. Biochem. Biophys. 263:1988;447-452.
36. Reynolds C.P., Perez-Polo J.R. Ascorbic acid enhances the cytotoxic effect of 6-hydroxydopamine for human neuroblastoma cell lines. Neurosci. Lett. 26:1981;151-155.
37. Thomas C.E., McLean L.R., Parker R.A., Ohlweiler D.F. Ascorbate and phenolic antioxidant interactions in prevention of liposomal oxidation. Lipids. 27:1992;543-550.
38. Driscoll J.S. Catecholamine analogs as potential antitumor agents. J. Pharm. Sci. 78:1979;1519-1521.
39. Bindoli A., Rigobello M.P., Deeble D.J. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic. Biol. Med. 13:1992;391-405.
40. Picardo M., Passi S., Nazzaro-Porro M. et al. Mechanism of antitumoral activity of catechols in culture. Biochem. Pharm. 36:1987;417-425.
41. Swartz M.N. Hospital-acquired infections: diseases with increasingly limited therapies. Proc. Natl. Acad. Sci. 91:1994;2420-2427.
42. Ecker G., Chiba P., Hitzler M. Structure activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance. J. Med. Chem. 39:1996;4767-4774.
43. Proudfoot J.R., Hargrave K.D., Kapadia S.R. et al. Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse. J. Med. Chem. 38:1995;4830-4838.
44. Artico M., Silvestri R., Pagnozzi E. et al. 5H-Pyrrolo[1,2-b][1,2,5]benzothia-diazepines (PBTDs): a novel class of non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. 4:1996;837-850.
45. Cushman M., Casimiro-Garcia A., Williamson K., Rice W.G. Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyidiarylmethane (ADAM) series with optimized potency and therapeutic index. Bioorg. Med. Chem. Lett. 8:1998;195-198.